intrahepatic cholangicarcinoma
Conditions
Interventions
Immunotherapy combined with chemotherapy group :N/A
Chemotherapy alone group :N/A
Sponsors
Ningbo Medical Centre Lihuili Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age>= 18 years; 2. Clinically diagnosed or confirmed by pathology or cytology as intrahepatic cholangiocarcinoma (ICC); 3. Clinically staged as locally advanced or metastatic (IIIB-IV stage) disease that is not surgically resectable; 4. Initiated first-line systemic treatment at this center between January 1, 2016, and June 30, 2025; 5. First-line treatment regimen is clearly defined as: A. PD-1/PD-L1 inhibitor combined with gemcitabine + cisplatin (cisplatin may be replaced with oxaliplatin or nedaplatin);or B. Gemcitabine + cisplatin (as above); 6. Available baseline and at least one post-treatment imaging evaluation data.
Exclusion criteria
Exclusion criteria: 1. Previously received systemic anti-tumor therapy for advanced disease; 2. Concurrent with other active malignancies (except cured cutaneous basal cell carcinoma or cervical carcinoma in situ); 3. Severe deficiency in medical records, making it impossible to evaluate primary efficacy or safety; 4. Concurrent participation in other interventional clinical trials that may interfere with the evaluation of the endpoints of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse event; | — |
Countries
China
Contacts
Public ContactCaide Lu
Ningbo Medical Centre Lihuili Hospital
Outcome results
None listed